PMC4170978_01
The axial CT scan at first diagnosis, showing a contrast-enhanced solid mass (arrow) in the right axilla, with a total extrapleural growth.
can-8-464fig1.jpg
PMC4170978_01_can-8-464fig1.jpg
figure1
The patient underwent a computed tomography (CT) scan, showing a contrast-enhanced solid mass in the right axilla, with a total extra-pleural growth (Figure 1).
An axial fused PET-CT image shows an intense FDG uptake of the same lesion showed in Figure 1.
can-8-464fig2.jpg
PMC4170978_01_can-8-464fig2.jpg
figure2
A positron emission tomography (PET)-CT scan (Figure 2), showed an intense Fludeoxyglucose (FDG) uptake of the lesion, and a subsequent ultrasound (US)-guided biopsy disclosed mesenchymal tumour with uncertain malignant potential.
An axial CT scan at recurrence, showing a contrast-enhanced solid tissue (arrow) along the right chest wall, infiltrating the intercostal muscles and the pectoralis muscles, demonstrated at biopsy as recurrence of AF.
can-8-464fig3.jpg
PMC4170978_01_can-8-464fig3.jpg
figure3
A follow-up CT scan performed 10 months after surgery disclosed local recurrence infiltrating the intercostal muscles, the pleura, and the pectoralis muscles (Figure 3).
Coronal post-Gd MR T1 weighted image with fat suppression, showing the presence of an irregular enhancing solid tissue along the right chest wall (arrows), infiltrating the adjacent pleura and lung.
can-8-464fig4.jpg
PMC4170978_01_can-8-464fig4.jpg
figure4
Subsequent MRI (Figure 4) demonstrated a 10 x 3.5 cm recurrence of AF, confirmed by the US-guided biopsy.
An axial CT scan, after 12 months of treatment, showing an initial downsizing of the lesion, contoured by a white line.
can-8-464fig5.jpg
PMC4170978_01_can-8-464fig5.jpg
figure5
The therapy prescribed included tamoxifen 20 mg/diem and celecoxib 200 mg/diem (anti-inflammatory COX-2 inhibitor), with good control of the symptoms and (initial) downsizing of the lesion after 12 months of treatment, as demonstrated by CT scan (Figure 5).